Company intelligence / Profile preview

Orca Bio

Menlo Park, California, United Statesorcabio.com ↗
Ownership
Private
Employees
~100
Development stage
Phase 1
01

Overview

Lead product Orca-T is in Phase 3 clinical trials (Precision-T) for treatment of AML, ALL, and MDS. Second-generation product Orca-Q is in Phase 1/2 trials.

Therapeutic areas
ImmunologyHematology
Modalities
High-precision cell therapiesAllogeneic T-cell immunotherapies
Industry
Biotech
02

Drug pipeline

7 assets

allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq (Stanford University)

Approved

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Orca Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orca Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call